This federal Project Grant award of $178,981 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Texas A&M University System Health Science Center on "Bacterial Flagellin-Driven LINE-1 Retrotransposon Activation: A New Frontier in Lung Cancer Research". The award, which runs from April 1, 2025 to March 31, 2026, will enable the university to conduct innovative scientific studies aimed at improving health outcomes for military service members, veterans, and the broader public through advanced biomedical research focused on lung cancer. As a prominent research institution, Texas A&M University System Health Science Center has a history of successfully delivering high-impact medical research projects as both a prime grantee and sub-awardee in collaboration with partners such as the University of Tennessee, Baylor College of Medicine, and University of Florida.
Generated 2/25/25, 4:04 AM